Ipca Laboratories Limited

IPCALAB

INE571A01038

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:29 2024-07-16 am EDT			5-day change	1st Jan Change
1,218 ^INR	-0.76%		-0.21%	+9.44%

Jul. 11	Ipca Laboratories Limited Announces Superannuation of Dr. Goutam Muhuri as President R&D (Formulations)	CI
May. 30	Transcript : Ipca Laboratories Limited, Q4 2024 Earnings Call, May 30, 2024

Ipca Laboratories Limited Announces Superannuation of Dr. Goutam Muhuri as President R&D (Formulations)

July 11, 2024 at 07:19 am EDT

Ipca Laboratories Limited informed that Dr. Goutam Muhuri, President R&D (Formulations) has superannuated from the services of the Company with effect from close of business hours on 11th July, 2024. Disclosure of relationships between directors:He is not related to any Director or Key Managerial Personnel of the Company.

Latest news about Ipca Laboratories Limited

Ipca Laboratories Limited Announces Superannuation of Dr. Goutam Muhuri as President R&D (Formulations)	Jul. 11	CI
Transcript : Ipca Laboratories Limited, Q4 2024 Earnings Call, May 30, 2024	May. 30
Ipca Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 29	CI
Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	May. 29	CI
Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories	May. 23	MT
Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director	Mar. 29	CI
Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director	Mar. 29	CI
Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary	Mar. 27	MT
Ipca Laboratories Limited Enters into A Technology Transfer Agreement with Omexa Formulary Pvt. Ltd	Mar. 27	CI
Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy	Feb. 19	MT
Transcript : Ipca Laboratories Limited, Q3 2024 Earnings Call, Feb 15, 2024	Feb. 15
Ipca Laboratories Limited Announces Appointment of Kamal Kishore Seth as the Lead Independent Director	Feb. 14	CI
Ipca Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Transcript : Ipca Laboratories Limited, Q2 2024 Earnings Call, Nov 10, 2023	Nov. 10
Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2023-24	Nov. 10	CI
Ipca Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Ipca Laboratories' Pithampur Plant Classified as VAI by US FDA	23-10-31	MT
Nomura Upgrades Ipca Laboratories to Buy From Neutral, Adjusts Price Target to INR1,133 From INR942	23-10-23	MT
INDIA STOCKS-Indian shares slide on Mideast jitters; ICICI Bank up on earnings beat	23-10-23	RE
Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)	23-10-16	CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion.	23-09-07	CI
Ipca Laboratories' Piparia Manufacturing Plant in India Gets VAI Classification from US FDA	23-08-24	MT
Nomura Adjusts IPCA Laboratories’ Price Target to INR942 From INR866, Keeps at Neutral	23-08-15	MT
Transcript : Ipca Laboratories Limited, Q1 2024 Earnings Call, Aug 11, 2023	23-08-11
Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI

Chart Ipca Laboratories Limited

Duration

Period

More charts

Company Profile

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Pharma Nigeria Ltd., Trophic Wellness Pvt. Ltd.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ipca Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,218 INR

Average target price

1,216 INR

Spread / Average Target

-0.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPCA LABORATORIES LIMITED	+9.44%	3.7B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals